26 completed, 5 terminated, 2 active not recruiting, 2 recruiting. 26 Phase 1, 6 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 22, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Terminated 2, Withdrawn 1 |
| Phase 3 | 4 | Active not recruiting 2, Completed 1, Terminated 1 |
Follow Atea Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AT-587 in Healthy Subjects AT-587, Placebo - Hepatitis E | Phase 1 | Recruiting | Atea Pharmaceuticals, Inc. | 62 | 2026-07-13 | 2026-07-27 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 24 | 2025-12-04 | 2026-04-13 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-06-02 | 2026-06-29 |
| Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 20 | 2025-05-09 | 2025-08-29 |
| Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination - Healthy Volunteer Study, Hepatic Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 28 | 2025-04-09 | 2026-07-31 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 38 | 2025-04-08 | 2025-08-29 |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL) - HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-04-07 | 2025-12-05 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR - Healthy Volunteer Study | Phase 1 | Recruiting | Atea Pharmaceuticals, Inc. | 32 | 2025-01-07 | 2026-07-16 |
| Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK, Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 28 | 2024-04-15 | 2024-07-31 |
| Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 42 | 2023-12-14 | 2024-09-19 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| The Study of Bemnifosbuvir in Healthy Japanese Subjects Bemnifosbuvir (BEM) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 14 | 2023-04-26 | 2023-06-15 |
| Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects Bemnifosbuvir (BEM), Placebo, Moxifloxacin - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 35 | 2023-04-25 | 2023-06-15 |
| Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 32 | 2023-01-30 | 2023-06-01 |
| Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function Bemnifosbuvir (BEM) - Healthy Volunteer, Hepatic Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 39 | 2023-01-30 | 2024-07-31 |
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 Bemnifosbuvir (BEM), Placebo - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19 | Phase 3 | Completed | Atea Pharmaceuticals, Inc. | 2285 | 2022-11-25 | 2025-06-13 |
| Study of AT-527 in Subjects With Normal and Impaired Renal Function AT-527, AT-527 and Probenecid - Healthy Volunteer, Renal Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 36 | 2022-10-17 | 2024-07-31 |
| Study of AT-752 in Patients With Dengue Infection AT-752, Placebo - Dengue Fever | Phase 2 | Terminated | Atea Pharmaceuticals, Inc. | 21 | 2022-04-29 | 2024-03-05 |
| Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model AT-752, Placebo Comparator - Dengue | Phase 1 | Terminated | Atea Pharmaceuticals, Inc. | 5 | 2022-04-22 | 2023-04-21 |
| Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal AT-527 fasted, Placebo Comparator fasted, AT-527 fed - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 136 | 2022-02-22 | 2022-10-18 |
Showing 20 of 36. Sign in to see all of them.
COVID-19 (5) · Hepatitis C (5) · Hepatitis C, Chronic (5) · Dengue (3) · Renal Insufficiency (2) · Flaviviridae Infections (1) · Hemorrhagic Fevers, Viral (1) · Hepatitis E (1) · Hepatitis, Viral, Human (1) · Infections (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Post-Acute COVID-19 Syndrome (1) · Vector Borne Diseases (1) · Virus Diseases (1)
AT-511 (23) · ruzasvir (4) · AT-752 (3) · sofosbuvir-velpatasvir drug combination (2) · Buprenorphine (1) · Carbamazepine (1) · Cyclosporine (1) · Digoxin (1) · Lead (1) · Levonorgestrel (1) · Midazolam (1) · Moxifloxacin (1) · Naloxone (1) · Omeprazole (1) · Probenecid (1)
Canada (17) · United States (12) · Belgium (7) · Brazil (6) · Romania (6) · Moldova (5) · Turkey (Türkiye) (5) · Argentina (4) · Germany (4) · India (4) · South Africa (4) · Spain (4) · Ukraine (4) · Mexico (3) · Pakistan (3)
Xiao-Jian Zhou, PhD (2) · Xiao-Jian Zhou (1)
PMID 31570394, PMID 37338393, PMID 37928891, PMID 38051993, PMID 38526047, PMID 42253092
2019 (2)